Enzo Biochem, Inc. filings document the public-company record for a life sciences tools issuer and its common stock. The filing record includes a Form 15 certification and notice covering termination of Exchange Act registration under Section 12(g) and suspension of reporting duties under Sections 13 and 15(d) for the company’s common stock.
Enzo’s current reports also cover material-event disclosures, material agreements, shareholder voting matters, capital-structure disclosures, governance matters, and operating and financial results tied to its life sciences business and corporate status.
Enzo Biochem, Inc. filed an S-8 post-effective amendment covering multiple prior employee benefit registration statements and stock plans. The filing lists historical registrations for aggregate share amounts ranging from 260,000 to 4,000,000 under various plans (1994 Plan, 1999 Plan, 2011 Incentive Plan, Profit Sharing Plan and inducement awards). The document is administrative: it reconfirms registration coverage for shares issuable under employee compensation arrangements and is signed by the Chief Financial Officer.
Enzo Biochem, Inc. submitted an S-8 post-effective amendment referencing multiple prior registration statements covering employee benefit and equity compensation plans. The filing lists historical registration statements (dating from 1983 through 2021) and specifies aggregate share amounts for several plans, including 988,951; 950,000; 1,000,000; 2,000,000; 3,000,000; 1,000,000; 2,000,000; 1,000,000; 4,000,000; and 960,000 shares across various plans. The filing is signed by Patricia Eckert, Chief Financial Officer.
Bradley Louis Radoff, a director of Enzo Biochem, Inc. (ENZ), reported on Form 4 that he disposed of a total of 4,533,779 non‑derivative equity interests and an additional 430,000 shares on 08/20/2025, leaving him with 0 shares beneficially owned. The filing explains the dispositions occurred pursuant to the Agreement and Plan of Merger dated June 23, 2025, under which Enzo merged into Bethpage Parent, Inc., and each share of Enzo common stock was canceled and converted into the right to receive $0.70 in cash per share (less withholding). Restricted stock units that vested solely by time for board members were likewise canceled and converted into cash based on the same $0.70 per‑share Merger Consideration. The report is a single‑person Form 4 filed by Radoff and is signed and dated 08/20/2025.
Steven J. Pully, a director of Enzo Biochem, Inc. (ENZ), reported on 08/20/2025 the disposition of 239,992 non-derivative securities in connection with a completed merger.
Per the Merger Agreement, each share of common stock was canceled and converted into the right to receive $0.70 in cash. The reported amount represents 142,897 restricted stock units that vested only by time and 79,365 shares of common stock, which were converted into cash at the merger consideration. Following the transaction the reporting person holds 0 shares.
Patricia Eckert, Chief Financial Officer of Enzo Biochem, Inc. (ENZB), reported transactions on 08/20/2025 related to the company's merger. At the effective time of the Merger, each outstanding share of Enzo common stock was canceled and converted into the right to receive $0.70 in cash per share, less applicable withholding taxes. The filing shows Ms. Eckert disposed of 28,328 shares of common stock and, separately, multiple outstanding stock options (totaling 275,000 options) were cancelled without payment or other consideration under the Merger Agreement. Following these transactions, Ms. Eckert reports owning 0 shares and 0 underlying shares from the cancelled options.
Enzo Biochem insider Jon Couchman reported that all of his holdings in the company were disposed of on 08/20/2025 in connection with a merger that made Enzo a wholly-owned subsidiary. At the Effective Time of the Merger, each share of common stock was cancelled and converted into the right to receive $0.70 in cash per share, net of taxes. The filing shows the cancellation/conversion of 142,897 RSUs and disposals of common stock held directly or indirectly through Xstelos Holdings, Myrexis, the Couchman Family Fund and his retirement accounts, leaving 0 shares beneficially owned following the transactions.
Enzo Biochem insider filings show the company's merger closed and equity holdings were converted or canceled. The reporting person, Kara Cannon, who served as Chief Executive Officer and director, disposed of 359,737 shares of common stock and 45,065 shares held indirectly in a 401(k) on 08/20/2025. Under the Merger Agreement dated June 23, 2025, each share of common stock was canceled and converted into the right to receive $0.70 in cash per share. Time-vested RSUs held by directors were similarly converted into cash based on underlying shares. Outstanding stock options were canceled at the Effective Time without any cash payment or other consideration.
Enzo Biochem, Inc. has completed its previously announced merger with Bethpage Parent, Inc., with Bethpage Merger Sub, Inc. merging into Enzo on August 20, 2025. Enzo survives the transaction as a wholly owned subsidiary of Bethpage Parent.
At the merger effective time, each outstanding share of Enzo common stock was converted into the right to receive $0.70 in cash, without interest and subject to applicable withholding taxes. Certain restricted stock units held by directors or already vested converted into cash based on the same per-share price, while all other RSUs and all stock options were canceled without payment. Outstanding warrants were canceled in exchange for cash amounts specified in individual warrant cancellation agreements.
The company’s common stock stopped trading on the OTCQX tier of the OTC Markets before the August 20, 2025 market open, and Enzo plans to file a Form 15 to deregister its common stock and suspend its SEC reporting obligations. A change in control occurred, and Enzo’s prior directors named in the report ceased serving at the merger effective time, with the certificate of incorporation and bylaws amended and restated in connection with the closing.
Enzo Biochem, Inc. held a special shareholder meeting on August 19, 2025 to vote on its planned merger with Bethpage Parent, Inc. and its wholly owned subsidiary Bethpage Merger Sub, Inc. Of the 52,352,764 common shares outstanding as of the July 15, 2025 record date, 34,336,390 shares were represented at the meeting, equal to about 65.58% of eligible shares.
Shareholders approved the merger agreement, with 29,964,566 votes for, 4,306,757 votes against, and 65,067 abstentions on the merger proposal. Because the merger proposal passed, a separate proposal to adjourn the meeting to solicit additional votes was not needed and was not presented. Subject to satisfaction or waiver of the remaining closing conditions in the merger agreement, the company and Bethpage Parent expect the merger to close on or about August 20, 2025.